Bailard’s Tandem Diabetes Care TNDM Stock Holding History

Bailard’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,373	Closed	-$259K	–	759
2022 Q2	$259K	Buy	4,373 +2,653	+154%	+$218K	0.01%	530
2022 Q1	$200K	Buy	+1,720	New	+$201K	0.01%	676

Other funds holding TNDM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bailard's TNDM Position: Q3 2022 in Review

Bailard sold out of Tandem Diabetes Care (TNDM) in Q3 2022, closing a stake of 4,373 shares — an estimated $259K sold.

Bailard first reported a position in TNDM in Q1 2022 and held it in 2 quarters. The position peaked at $259K in Q2 2022. 299 funds tracked by Wall St. Rank hold TNDM as of Q3 2022.

Bailard reported no remaining Tandem Diabetes Care position as of Q3 2022 after selling out during the quarter.
Bailard sold 4,373 Tandem Diabetes Care shares in Q3 2022, an estimated $259K.
Bailard first reported a position in Tandem Diabetes Care in Q1 2022 and held it in 2 quarters.
Bailard's Tandem Diabetes Care position peaked at $259K in Q2 2022.
299 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2022.

Based on Bailard's 13F filing for Q3 2022, filed 18 Oct 2022.